Literature DB >> 15882268

Progression of secondary hyperparathyroidism involves deregulation of genes related to DNA and RNA stability.

Iñigo Santamaría1, Daniel Alvarez-Hernández, Rosa Jofré, José Ramón Polo, Javier Menárguez, Jorge B Cannata-Andía.   

Abstract

BACKGROUND: Renal secondary hyperparathyroidism in its late stages becomes autonomous, so excessive parathyroid hormone (PTH) secretion no longer responds to physiologic stimuli or to aggressive medical treatment.
METHODS: To gain molecular understanding of progression of renal secondary hyperparathyroidism, normal and hyperplastic parathyroid tissue with diffuse and nodular growth were analyzed. The results were also compared to parathyroid adenomas. The analysis was performed by high-density oligonucleotide microarray and bidirectional subtraction library.
RESULTS: Analysis of the DNA arrays found 16 overexpressed and 132 repressed genes in the nodules while the subtraction library produced 34 overexpressed and 40 repressed genes. The differentially expressed genes between diffuse and nodular samples included some related to DNA stability and repair (TALDO1, PRDX2, DDB1, XRCC1, and POLB), RNA stability and degradation (OASL and AUF1), protein synthesis and processing (PFDN5, HSPD1, and NACA), cell growth (CDC25C and GRPR), and tumorigenesis and cell cycle (VIL2 and TPD52).
CONCLUSION: According to the function described for the deregulated genes, when secondary hyperparathyroidism becomes autonomous and refractory to treatment, RNA degradation may be increased while DNA integrity may be compromised. These two mechanisms, combined with deregulation of genes related to growth and differentiation show the complex pathway of parathyroid glands' evolution in renal hyperparathyroidism and may explain the large amount of molecular cytogenetic aberrations found in refractory hyperparathyroidism. Considering that some of the genes with altered expression in nodular hyperplasia lead to irreversible consequences in the genomic integrity of the cells, an adequate and early management of the secondary hyperparathyroidism of chronic kidney disease becomes mandatory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882268     DOI: 10.1111/j.1523-1755.2005.00330.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Serum nuclear factor IB as a novel and noninvasive indicator in the diagnosis of secondary hyperparathyroidism.

Authors:  Jian'gen Yu; Yu Song; Aihua Yang; Xiaoyun Zhang; Lin Li
Journal:  J Clin Lab Anal       Date:  2021-05-15       Impact factor: 2.352

2.  Systems genetics analysis of mouse chondrocyte differentiation.

Authors:  Jaijam Suwanwela; Charles R Farber; Bau-Lin Haung; Buer Song; Calvin Pan; Karen M Lyons; Aldons J Lusis
Journal:  J Bone Miner Res       Date:  2011-04       Impact factor: 6.741

Review 3.  Molecular Mechanisms of Parathyroid Disorders in Chronic Kidney Disease.

Authors:  Alia Hassan; Nareman Khalaily; Rachel Kilav-Levin; Morris Nechama; Oded Volovelsky; Justin Silver; Tally Naveh-Many
Journal:  Metabolites       Date:  2022-01-25

Review 4.  Mechanism of calcitriol regulating parathyroid cells in secondary hyperparathyroidism.

Authors:  Zeli Xiang; Ming Wang; Changxiu Miao; Die Jin; Hongyue Wang
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

5.  Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease.

Authors:  Willeke M C van Roon-Mom; Barry A Pepers; Peter A C 't Hoen; Carola A C M Verwijmeren; Johan T den Dunnen; Josephine C Dorsman; Gertjan B van Ommen
Journal:  BMC Mol Biol       Date:  2008-10-09       Impact factor: 2.946

Review 6.  Prefoldin Function in Cellular Protein Homeostasis and Human Diseases.

Authors:  Ismail Tahmaz; Somayeh Shahmoradi Ghahe; Ulrike Topf
Journal:  Front Cell Dev Biol       Date:  2022-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.